(±)-Catechin (Synonyms: rel-Cianidanol; rel-Catechuic acid)

Name: (±)-Catechin
Brand: MedChemExpress
SKU: HY-B1890
Rating: 4.5 (1 reviews)

Cat. No.: HY-B1890 Purity: 98.38%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

(±)-Catechin (rel-Cianidanol) This is a green tea polyester. Catechin possesses anti-cancer activity, which has led to its demise. (±)-Catechin 具有两种forms (+)-Catechin and its reflection body (-)-Catechin. (+)-Catechin inhibitory environment-1 (COX-1) IC₅₀ 为 1.4 μM. (-)-Catechin has the effect of promoting hBM-MSC adipose cell differentiation, increasing adipose tissue, and PPARγ horizontal. (±)-Catechin has anti-diabetic, anti-hypertrophic, anti-diabetic, anti-cardiovascular, anti-infective, and liver-protecting effects.

For research use only. We do not sell to patients.

(±)-Catechin Chemical Structure

CAS No. : 7295-85-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of (±)-Catechin:

1 Publications Citing Use of MCE (±)-Catechin

•Mol Med Rep. 2024 Feb;29(2):26. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	> 10 μg/mL Compound: page 1629, R25C1	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 17125236]
A549	IC₅₀	> 10 μg/mL Compound: page 1629, R25C1	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 17125236]
A549	ED₅₀	> 10 μg/mL Compound: 46	Cytotoxicity against human A549 cells by tetrazolium salt-based colorimetric assay Cytotoxicity against human A549 cells by tetrazolium salt-based colorimetric assay	[PMID: 1431932]
Bel-7402	IC₅₀	> 10 μg/mL Compound: page 1629, R25C1	Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay	[PMID: 17125236]
BGC-823	IC₅₀	> 10 μg/mL Compound: page 1629, R25C1	Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay	[PMID: 17125236]
BMDC	IC₅₀	> 50 μM Compound: 16	Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDC	IC₅₀	> 50 μM Compound: 16	Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDC	IC₅₀	> 50 μM Compound: 16	Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BV-2	IC₅₀	9.52 μM Compound: 12	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction	[PMID: 27623545]
H9	EC₅₀	> 345 μM Compound: 20	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	> 345 μM Compound: 20	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
HCT-8	IC₅₀	> 10 μg/mL Compound: page 1629, R25C1	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 17125236]
HCT-8	ED₅₀	> 10 μg/mL Compound: 46	Cytotoxicity against human HCT8 cells by tetrazolium salt-based colorimetric assay Cytotoxicity against human HCT8 cells by tetrazolium salt-based colorimetric assay	[PMID: 1431932]
KB	ED₅₀	> 10 μg/mL Compound: 46	Cytotoxicity against human KB cells by tetrazolium salt-based colorimetric assay Cytotoxicity against human KB cells by tetrazolium salt-based colorimetric assay	[PMID: 1431932]
MT4	IC₅₀	> 86.8 μg/mL Compound: 12	Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 10425115]
MT4	CC₅₀	86.8 μg/mL Compound: 12	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 10425115]
Platelet	IC₅₀	> 50 μg/mL Compound: (+)-Catechin	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	27.65 μg/mL Compound: (+)-Catechin	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 21106454]
TE-671	ED₅₀	> 10 μg/mL Compound: 46	Cytotoxicity against human TE671 cells by tetrazolium salt-based colorimetric assay Cytotoxicity against human TE671 cells by tetrazolium salt-based colorimetric assay	[PMID: 1431932]

In Vitro

(-)-catechin (10 μM; a 2-day cycle for 12 days in total) induces adipocyte differentiation of human bone marrow mesenchymal stem cells (hBM-MSC), increases adiponectin levels, and increased PPARγ transcription^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

290.27

Formula

C₁₅H₁₄O₆

CAS No.

7295-85-4

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1[C@H](OC2=CC(O)=CC(O)=C2C1)C3=CC=C(C(O)=C3)O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (430.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4451 mL	17.2253 mL	34.4507 mL
5 mM	0.6890 mL	3.4451 mL	6.8901 mL
10 mM	0.3445 mL	1.7225 mL	3.4451 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.38%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (249 KB) HNMR (286 KB) LCMS (250 KB)

Handling Instructions (2659 KB)

References

[1]. Mamoru Isemura. Catechin in Human Health and Disease. Molecules. 2019 Feb 1;24(3):528. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.4451 mL	17.2253 mL	34.4507 mL	86.1267 mL
	5 mM	0.6890 mL	3.4451 mL	6.8901 mL	17.2253 mL
	10 mM	0.3445 mL	1.7225 mL	3.4451 mL	8.6127 mL
	15 mM	0.2297 mL	1.1484 mL	2.2967 mL	5.7418 mL
	20 mM	0.1723 mL	0.8613 mL	1.7225 mL	4.3063 mL
	25 mM	0.1378 mL	0.6890 mL	1.3780 mL	3.4451 mL
	30 mM	0.1148 mL	0.5742 mL	1.1484 mL	2.8709 mL
	40 mM	0.0861 mL	0.4306 mL	0.8613 mL	2.1532 mL
	50 mM	0.0689 mL	0.3445 mL	0.6890 mL	1.7225 mL
	60 mM	0.0574 mL	0.2871 mL	0.5742 mL	1.4354 mL
	80 mM	0.0431 mL	0.2153 mL	0.4306 mL	1.0766 mL
	100 mM	0.0345 mL	0.1723 mL	0.3445 mL	0.8613 mL

(±)-Catechin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(±)-Catechin7295-85-4rel-Cianidanol rel-Catechuic acidCOXCyclooxygenase(±)-Catechin is the racemate of Catechin. (±)-Catechinderived from catechu of the extract of Acacia catechu L. with two steric forms of (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. Anticanceranti-obesityantidiabeticanticardiovascularanti-infectioushepatoprotectiveand neuroprotective effects. （±）-儿茶素 (±)-Catechin 是Catechin的外消旋体。(±)-Catechin，从 Acacia catechu L. 中提取，具有两种形式(+)-Catechin及其对映体（-）-Catechin。(+)-Catechin 抑制环氧合酶-1（COX-1）的IC50为1.4μM。 (±)-Catechin 具有抗肿瘤，抗肥胖，抗糖尿病，抗心血管，抗感染，保肝和神经保护作用。Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

(±)-Catechin (Synonyms: rel-Cianidanol; rel-Catechuic acid)

Customer Review

Other Forms of (±)-Catechin:

(±)-Catechin Related Antibodies

1 Publications Citing Use of MCE (±)-Catechin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

(±)-Catechin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

(±)-Catechin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report